An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema (CONVERT_II)

March 11, 2026 updated by: Pulmonx Corporation

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema: The CONVERT II Trial

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a multicenter, prospective, single-arm, pivotal trial with a 24-month follow-up to evaluate the safety and effectiveness of the AeriSeal System to block CV. The study plans to enroll up to 200 subjects at up to 35 clinical centers in US and OUS. Study subjects will be patients with severe, heterogeneous emphysema and collateral ventilation in the lobe targeted who are candidates for BLVR. Subjects meeting initial eligibility will undergo a bronchoscopy procedure under general anesthesia during which the presence of CV will be confirmed using Chartis. All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure. Conversion of collateral ventilation status from CV+ to CV- in the target lobe will be evaluated by Chartis at Day 45 post-AeriSeal treatment (primary effectiveness endpoint). All subjects not converted from CV+ to CV- status will undergo a repeat of the AeriSeal procedure, provided that the total volume from both the initial and the repeat treatments does not exceed 40 mL in up to 3 segments. All subjects converted from CV+ to CV- status after either the index or repeat AeriSeal procedure will undergo BLVR with Zephyr Valve per standard of care in accordance with the approved instructions for use and will be followed through Month 24 (end of study). All CV+ subjects who remain CV+ after the repeat procedure or do not undergo the repeat AeriSeal procedure will be followed through Month 24 (end of study).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
200

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Australia
  • Austria
  • Denmark
    • Denmark
      • Copenhagen, Denmark, Denmark
        • Withdrawn
        • Rigshospitalet
  • France
  • Germany
  • Italy
  • Netherlands
    • Netherlands
      • Groningen, Netherlands, Netherlands
        • Recruiting
        • University Medical Center Groningen
        • Principal Investigator:
          • Dirk-Jan Slebos, MD
        • Contact:
        • Contact:
  • Spain
    • Spain
      • Valencia, Spain, Spain
        • Recruiting
        • Hospital Universitario Y Politecnico La Fe
        • Contact:
        • Principal Investigator:
          • Enrique Cases Viedma, MD
        • Contact:
  • United Kingdom
    • England
      • London, England, United Kingdom
        • Recruiting
        • Royal Brompton Hospital
        • Principal Investigator:
          • Pallav Shah, MD
        • Contact:
        • Contact:
  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85006
    • Connecticut
      • Hartford, Connecticut, United States, 06105
    • Florida
    • Illinois
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
      • Boston, Massachusetts, United States, 02115
        • Withdrawn
        • Brigham Lung Center
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Hospital
        • Principal Investigator:
          • Avi Cohen, MD
        • Contact:
        • Contact:
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Withdrawn
        • Cleveland VA Northeast
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19140
      • Philadelphia, Pennsylvania, United States, 19107
      • Pittsburgh, Pennsylvania, United States, 15212
        • Recruiting
        • Allegheny General Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stephanie Baltaji, MD
      • Pittsburgh, Pennsylvania, United States, 15213
        • Recruiting
        • University of Pittsburgh Medical Center (UPMC)
        • Principal Investigator:
          • Frank Sciurba, MD
        • Contact:
        • Contact:
    • Tennessee
      • Knoxville, Tennessee, United States, 37916
        • Recruiting
        • Fort Sanders Regional Medical Center (StatCare)
        • Contact:
        • Principal Investigator:
          • Varun Shah, MD
        • Contact:
    • Texas
    • Virginia
      • Falls Church, Virginia, United States, 22042
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • Medical College of Wisconsin (MCW)
        • Principal Investigator:
          • Jonathan Kurman, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Subject is willing and able to provide informed consent and to participate in the study.
  2. Subject is aged ≥ 40 and ≤ 80 years at the time of the ICF signature date.
  3. Subject has completed a documented pulmonary rehabilitation (in clinic or home-based) program within 12 months prior to Baseline.
  4. Subject has stopped smoking for at least 8 weeks prior to the ICF signature date as confirmed by carboxyhemoglobin or cotinine levels.

  5. Subject has a recent HRCT meeting the scan parameter requirements and performed within 3 months of the ICF signature date with the following findings at -910 Hounsfield Units:

    1. At least one (1) lobe with segmental emphysema destruction score ≥ 50%.
    2. Subject has heterogenous emphysema, defined as difference in emphysema destruction score of ≥ 15 between the density scores of the target lobe and the ipsilateral non-target lobe(s) per QCT report with % voxel density of < -910 HU. For non-target lobes that include the RML, calculate the combination of non-target lobes as a single density score using volume-weighted percent.
    3. LUL, LLL, RUL, RLL, or RUL+RML are targets for valve intervention.
    4. Subject has a gap in the interlobar fissure that corresponds to one or more segments and the fissure(s) contacting the target lobe is ≥ 80% complete per QCT report.
    5. Subject has 98% of the fissure gap confined to a maximum of 3 segments within the target lobe per Fissure Targeting Report (FTR).
  6. Subject has 6MWD ≥ 150 m and ≤ 450 m.
  7. Subject has clinically significant dyspnea with an mMRC score of ≥ 2.
  8. Subject has post-bronchodilation FEV1 ≥ 15% predicted and ≤ 45% predicted.
  9. Subject has an FEV1/FVC ratio of < 0.7.
  10. Subject has post-bronchodilation TLC, measured by body plethysmography, ≥ 100% predicted.
  11. Subject has post-bronchodilation RV ≥ 175% predicted, measured by body plethysmography.
  12. Subject has post-bronchodilation DLCO ≥ 20% predicted.
  13. Subject has received preventative vaccinations against potential respiratory infections, including COVID-19, consistent with local recommendation or policy.
  14. Subject is on optimal medical management for more than one month prior to the ICF signature date.
  15. Subject has collateral ventilation (CV+) as confirmed per the Chartis assessment prior to the AeriSeal Index Procedure.

Exclusion Criteria:

  1. Subject has prior lung volume reduction surgery, lobectomy or pneumonectomy, lung transplantation, airway stent placement, pleurodesis, or BLVR of any type, except BLVR using Zephyr Valve with < 50% TLVR at 6 months, followed by valve removal > 6 months prior to ICF signature date.
  2. Subject has visible radiological abnormality on HRCT scan such as pulmonary nodule greater than 0.8 cm in diameter (does not apply, if present for 2 years or more without increase in size or if deemed benign by biopsy) or active pulmonary infection (e.g., unexplained parenchymal infiltrate, significant interstitial lung disease or significant pleural disease).
  3. Post-COVID-19 pathology on CT, including ground glass opacities with or without consolidation, adjacent pleura thickening, interlobular septal thickening, or air bronchograms.
  4. Large bullae encompassing greater than 1/3 of the total lung.
  5. Subject had 3 or more COPD exacerbations requiring hospitalization within 12 months preceding the ICF signature date or a COPD exacerbation requiring hospitalization within 8 weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
  6. Subject has asthma as their primary diagnosis.
  7. Subject has chronic bronchitis (defined as greater than 4 tablespoons of sputum production per day) as their primary diagnosis.
  8. Subject has clinically significant bronchiectasis.
  9. Subjects with evidence of active respiratory infection should be considered for enrollment only after satisfactory resolution.
  10. Subject requires invasive ventilatory support. Note: The use of Continuous Positive Airway Pressure (CPAP) or BiPAP devices for sleep apnea is permitted.

  11. Subject has severe gas exchange abnormalities as defined by any one of the following tests, conducted at rest, on room air, as tolerated.

    • PaCO2 ≥ 50 mm Hg (6.7 kPa)
    • PaO2 < 45 mm Hg (6.0 kPa)
  12. Subject has pulmonary hypertension, defined as mean pulmonary systolic pressure > 45 mm Hg.
  13. Subject has known documented alpha-1 antitrypsin deficiency.
  14. Subject has clinically significant hematological disorder.
  15. Subject has recent significant unplanned or unexplained weight loss or other relevant comorbidities considered by the investigator to be potentially confounding or limiting to the subject's participation in the study.
  16. Subject has non-atrial arrhythmias or conduction abnormalities on EKG.
  17. Subject has high cardiac risk after undergoing cardiac risk assessment in accordance with published guidelines (Fleisher 2007) or has ischemic heart disease, congestive heart failure, cerebrovascular disease (stroke or TIA within 6 months of the ICF signature date), serum creatinine > 2.0 mg/dL (177 μmol/L), or left ventricular ejection fraction (LVEF) < 45% on echocardiogram.
  18. Subject has uncontrolled exercise induced syncope.
  19. Subject has evidence of severe disease which in the judgment of the investigator may compromise the anticipated treatment effect or the subject's survival for the duration of at least 12 months.
  20. Subject has any other condition that the investigator believes would interfere with the intent of the study or would make participation not in the best interest of the subject including but not limited to alcoholism, high risk for drug abuse, or noncompliance in returning for follow-up visits.
  21. Subject cannot tolerate corticosteroids or relevant antibiotics.
  22. Subject use of systemic corticosteroids > 20 mg/day prednisolone or equivalent within four (4) weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
  23. Subject use of immunosuppressive agents within four (4) weeks of the ICF signature date. Subjects may be re-considered for future enrollment.
  24. Subject is unable to temporarily discontinue heparins and oral anticoagulants (e.g., warfarin, dicumarol) according to local pre-procedural protocols. Note: Antiplatelet drugs including aspirin, thienopyridines and ticagrelor are permitted.
  25. Subject has allergy or sensitivity to medications required to safely perform bronchoscopy under conscious sedation or general anesthesia.
  26. Subject has known allergy to the following device components: Polyether block amide (PEBAX), Polyvinyl Alcohol or Glutaraldehyde, Nitinol (nickel-titanium) or its constituent metals (nickel or titanium) or Silicone.
  27. Subject is a female who is pregnant (positive βHCG Pregnancy test), breast-feeding, or planning to be pregnant in the next 12 months.
  28. Subject has Body Mass Index < 18 kg/m2 or > 35 kg/m2.
  29. Subject participated in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the ICF signature date. Note: Subjects being followed as part of a long-term surveillance of a non-pulmonary study that has reached its primary endpoint are eligible for participation in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: AeriSeal
All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure to block collateral ventilation by closing the lobar fissure gaps or collateral air channels.
Device: AeriSeal System
The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Converters, responder rate
Time Frame: 45 days post-AeriSeal treatment (index or repeat)
The percentage of study subjects that successfully convert from a positive collateral ventilation status (CV+) in the treated lobe to having little to no collateral ventilation (CV-) by Chartis.
45 days post-AeriSeal treatment (index or repeat)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Post-bronchodilator forced expiratory volume in 1 second (FEV1), responder rate
Time Frame: Month 6 post-Zephyr Valve
The percentage of converters achieving a ≥ 12% increase in FEV1
Month 6 post-Zephyr Valve
Residual volume (RV), responder rate
Time Frame: Month 6 post-Zephyr Valve
The percentage of converters achieving a ≥ 310 mL decrease in RV
Month 6 post-Zephyr Valve
Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), responder rate
Time Frame: Month 6 post-Zephyr Valve
The percentage of converters achieving a ≥ 350 mL decrease in TLVR
Month 6 post-Zephyr Valve
St. George's Respiratory Questionnaire (SGRQ), responder rate
Time Frame: Month 6 post-Zephyr Valve
The percentage of converters achieving a ≥ 4-point decrease in SGRQ total score
Month 6 post-Zephyr Valve

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Post-bronchodilator forced expiratory volume in 1 second (FEV1) change
Time Frame: Month 3, Month 6, Month 12, Month 24
Absolute, percent and percent predicted change
Month 3, Month 6, Month 12, Month 24
Post-bronchodilator forced expiratory volume in 1 second (FEV1), responder rate
Time Frame: Month 3, Month 12, Month 24
Percentage of subjects achieving a ≥12% increase
Month 3, Month 12, Month 24
Residual volume (RV), responder rate
Time Frame: Month 3, Month 12, Month 24
The percentage of subjects achieving a ≥ 310 mL decrease in RV
Month 3, Month 12, Month 24
Residual volume (RV), change
Time Frame: Day 45, Month 6, Month 12
Absolute and percent predicted change in RV
Day 45, Month 6, Month 12
Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), change
Time Frame: Day 45, Month 6, Month 12
Absolute change in TLVR
Day 45, Month 6, Month 12
Treated lobe volume reduction (TLVR) by high-resolution computed tomography (HRCT), responder rate
Time Frame: Day 45, Month 12
The percentage of subjects achieving a ≥ 350 mL decrease in TLVR
Day 45, Month 12
Residual volume to total lung capacity (RV/TLC) ratio
Time Frame: Month 3, Month 6, Month 12, Month 24
Absolute change in RV/TLC ratio
Month 3, Month 6, Month 12, Month 24
Forced vital capacity (FVC), change
Time Frame: Month 3, Month 6, Month 12, Month 24
Absolute and percent change in FVC
Month 3, Month 6, Month 12, Month 24
Diffusion capacity of carbon monoxide (DLCO), change
Time Frame: Month 6, Month 12
Absolute and percent predicted change in DLCO
Month 6, Month 12
Chronic Obstructive Pulmonary Disease assessment test (CAT), change
Time Frame: Month 3, Month 6, Month 12
Absolute change. Minimum score: 0, maximum score: 40. Lower scores indicate a better outcome.
Month 3, Month 6, Month 12
Chronic Obstructive Pulmonary Disease assessment test (CAT), responder rate
Time Frame: Month 3, Month 6, Month 12
The percentage of subjects achieving a ≥ 2-point decrease
Month 3, Month 6, Month 12
St. George's Respiratory Questionnaire (SGRQ), total score change
Time Frame: Month 3, Month 6, Month 12
Absolute change in SGRQ total score. Minimum score: 0, maximum score: 100. Lower scores indicate a better outcome.
Month 3, Month 6, Month 12
St. George's Respiratory Questionnaire (SGRQ), responder rate
Time Frame: Month 3, Month 12
The percentage of converters achieving a ≥ 4-point decrease in SGRQ total score
Month 3, Month 12
Six Minute Walking Test (6MWT), responder rate
Time Frame: Month 6, Month 12
Percentage of subjects achieving a ≥ 26 meter increase
Month 6, Month 12
Modified Medical Research Council (mMRC) Dyspnea Scale, total score change
Time Frame: Month 3, Month 6, Month 12
Absolute change in total mMRC Dyspnea Scale score. Minimum score: 0, maximum score: 4. Lower scores indicate a better outcome.
Month 3, Month 6, Month 12
Modified Medical Research Council (mMRC) Dyspnea Scale, responder rate
Time Frame: Month 3, Month 6, Month 12
The percentage of subjects achieving a ≥ 1-point decrease
Month 3, Month 6, Month 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Pulmonx Corporation

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Narinder Shargill, PhD, Pulmonx Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 22, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 5, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 13, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 13, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 630-2000-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

All data will be aggregated and analyzed. No IPD be made available for sharing to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings